Tag: GlobeNewswire

BROSSARD, Quebec, Oct. 08, 2026 (GLOBE NEWSWIRE) — G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX: GMIN, OTCQX: GMINF) is pleased to report preliminary production results for the quarter ended September 30, 2026 from its 100%-owned Tocantinzinho Gold Mine (“TZ”) in Pará State, Brazil.

TZ produced 44,960 ounces (“oz”) of gold (“Au”) in the third quarter of 2026, a 22% increase over Q2 2026. On a year-to-date basis, the Corporation has produced and sold 113,651 oz Au and 114,325 oz Au, respectively, putting the Corporation on track to achieve the midpoint of full-year production guidance of 160,000 to 190,000 oz Au.

Preliminary Third Quarter 2026 Operational Results Highlights:

• Gold produced: 44,960 oz
• Gold sold: 43,110 oz
• Average plant throughput: 12,372 tpd
• Average grade processed: 1.33 g/t Au
• Gold recovery: 92.0%
• Strip ratio: 2.47x

“Our third quarter operational results were solid and delivered the step-up in production we expected to support a strong second half of the year, with higher grades and improved gold recoveries driving production of 44,960 ounces for the quarter,” commented Louis-Pierre Gignac, President and Chief Executive Officer of GMIN. “TZ continues to perform very well, with mining rates averaging 74,209 tpd during the quarter, a 7% increase over Q2 2026. Throughput rates at the processing plant averaged 12,372 tpd with gold grades of 1.33 grams per tonne and gold recoveries of 92.0%, representing the strongest quarterly results year-to-date.”

“Mining activities remain closely aligned with the mine plan, enabling access to higher-grade Phase 2 mineralization and positioning the operation for a significant increase in grade and production in Q4,” continued Mr. Gignac. “Building on the strong operational performance delivered this quarter and together with the continued advancement of our exploration programs, we expect to deliver a strong finish to 2026 and carry that momentum into 2027.”

Table 1. TZ Preliminary Third Quarter 2026 Operational Results

		Q3 20261		Q3 2025		YTD 2026
Mining Activities
Ore Tonnes Mined	kt	1,966		1,787		4,659
Waste Tonnes Mined	kt	4,861		3,275		14,005
Total Tonnes Mined	kt	6,827		5,062		18,664
Strip Ratio	Waste/Ore	2.47		1.83		3.01
Processing Activities
Total Tonnes Processed	kt	1,138		1,094		3,213
Avg. Plant Throughput	tpd	12,372		11,890		11,770
Avg. Gold Recovery	%	92.0	%	92.3	%	91.5	%
Avg. Gold Grade Processed	g/t Au	1.33		1.43		1.20
Gold Produced	oz	44,960		46,360		113,651
Gold Sold	oz	43,110		49,119		114,325

1. Q3 2026 operating results are preliminary and subject to final reconciliation. Comparative Q3 2025 operating data are derived from the Corporation’s previously reported results.

Third Quarter 2026 Conference Call Details
The Corporation expects to release its third quarter 2026 financial and operating results after market close on Thursday, November 12, 2026. Senior management will host a conference call and webcast on Friday, November 13, 2026, at 9:00 a.m. (ET) to discuss the results. Participants may join using the following details:

• Conference ID: 9520726
• Toll-Free (North America): 1 (800) 715-9871
• International: 1 (646) 307-1963
• Webcast Link: https://edge.media-server.com/mmc/p/tutmtad5

The conference call will also be accessible through the GMIN investor relations website at: https://investors.gmin.gold/English/events-and-presentations/default.aspx

About G Mining Ventures Corp.
G Mining Ventures Corp. is a mining company engaged in the development, operation and exploration of precious metals projects. GMIN is well-positioned to grow into the next mid-tier precious metals producer by leveraging strong access to capital and proven development expertise. GMIN is currently anchored by the Tocantinzinho Mine in Brazil, supported by the Gurupi Project in Brazil and the Oko Gold Project in Guyana — all with significant exploration upside and located in mining-friendly jurisdictions. GMIN trades on the TSX under the symbol “GMIN” and its shares are quoted on the OTCQX network under the symbol “GMINF”.

Additional Information
For further information on GMIN, please visit the website at www.gmin.gold or contact:

Jean-François Lemonde 
Vice President, Investor Relations 
514.299.4926

Cautionary Statement on Forward-Looking Information 

All statements, other than statements of historical fact, contained in this press release constitute “forward-looking information” and “forward-looking statements” within the meaning of certain securities laws and are based on expectations and projections as of the date of this press release. Forward-looking statements contained in this press release include, without limitation, those related to (i) the Corporation remaining on track to achieve the midpoint of full-year production guidance; (ii) the anticipated access to higher-grade Phase 2 mineralization; (iii) production of Q4-2026 expected to lead to a strong finish to 2026; and (iv) the quoted comments of GMIN’s Chief Executive Officer, as well as the whole contents of the section entitled “About G Mining Ventures Corp.”.

Forward-looking statements are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Such assumptions include, without limitation, those relating to GMIN continuing to improve operational results and generate free cash flow as well as profitability, those relating to the price of gold and currency exchange rates, those outlined in feasibility and other technical studies relating to GMIN’s mining assets, and those underlying the items listed on the above section entitled “About G Mining Ventures Corp.”.

Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that, notably but without limitation, (i) TZ will continue operating and delivering production, recoveries and costs that will remain in line with expectations; (ii) GMIN will achieve the midpoint of full-year production guidance; (iii) a meaningful increase in grade and production will take place in Q4-2026; (iv) mining activities will remain closely aligned with the mine plan; (v) the higher-grade Phase 2 mineralization will be accessed in Q4-2026, or at all; (vi) Oko West will be brought into commercial production in 2028, or at all; or (vii) GMIN will use TZ and Oko West to grow into the next mid-tier precious metals producer, as future events could differ materially from what is currently anticipated by the Corporation. In addition, there can be no assurance that Brazil and/or Guyana will remain mining friendly and prospective jurisdictions.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as several important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Corporation’s other filings with the securities regulators of Canada including, but not limited to, the cautionary statements made in the relevant sections of the Corporation’s (i) Annual Information Form dated March 25, 2026, for the financial year ended December 31, 2025, and (iii) Management Discussion & Analysis. The Corporation cautions that the foregoing list of factors that may affect future results is not exhaustive, and new, unforeseeable risks may arise from time to time. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Anchorage, Alaska, Oct. 08, 2026 (GLOBE NEWSWIRE) — Nova Minerals Corp (“Nova Minerals” or the “Company”) (NYSE American: NVA | ASX: NVA) is pleased to report all key plant equipment for its planned antimony processing and refinery operation arrived at Port MacKenzie, Alaska, on October 6, 2026.

The arrival of the final major pieces of equipment enables construction of the processing and refinery facility to begin in the coming weeks, subject to receipt of the remaining permits.

This represents another significant milestone in the Company’s plan to establish a secure, vertically integrated U.S. domestic antimony supply chain in Alaska, supported by a $43.4 million award from the U.S. Department of War (DoW).

The key equipment shipment arrives as the 2026 field season at the Estelle Critical Minerals and Gold Project draws to a close, with initial assay results expected in due course.

In parallel, construction continues to advance across key infrastructure projects at Estelle, including the Korbel Stibium access road and airstrip expansion.

Highlights

• Additional Key Antimony Plant Equipment Delivered: All remaining antimony processing and refinery equipment has arrived on site. The delivery included two ball mills, a jaw crusher, apron feeder, hydraulic filter presses, and other ancillary equipment required for the antimony recovery process (Figure 1). This follows a 500-ton shipment of processing and refining equipment that arrived at Port Mackenzie on September 6.
• Antimony Plant Construction to Commence: Early earthworks are underway at Port MacKenzie (Figure 2), with construction of the antimony processing and refinery facility to commence, following receipt of final permits.
• 2026 Field Program Completed: An extensive ~8,000m diamond drilling program at Estelle, which focused on infill and resource expansion at the RPM gold deposit to advance the Pre-Feasibility Study (PFS), is now complete. The Stibium and Styx antimony prospects are progressing towards potential resource delineation and production. Samples and drill core from the 2026 field program have been prepared and shipped for analysis, and the Company expects to report results in due course.
• Estelle Site Infrastructure Construction Continues: The Korbel-Stibium access road (Figure 3) and Whiskey Bravo airstrip expansion (Figure 4) continue to make important progress.

Nova CEO, Mr. Christopher Gerteisen, commented:

“This equipment delivery brings Nova Minerals a step closer to establishing a secure, vertically integrated antimony supply chain for the United States domestic market.

“The U.S Department of War has designated antimony as a strategic priority for national and economic security, due to its necessity in defense, energy storage, and advanced electronic applications.

“While our 2026 field season, supported by three diamond rigs operating from June through September, has now concluded, activity at both Estelle and Port MacKenzie is continuing at pace. Favorable fall conditions provide an ideal window for earthworks and construction, with these activities set to continue through the winter months.”

Port MacKenzie Antimony Processing and Refinery Facility

The remaining shipment of key ore processing and refining equipment included another 10 truckloads, and follows more than 40 containers that arrived by barge at Port MacKenzie on September 6.

Nova sourced modern processing and milling equipment from a recently decommissioned site in North America to accelerate construction and deliver meaningful cost savings, with first antimony expected in 2027.

Early earthworks are underway (Figure 2), with construction of the antimony processing facility, which is designed to process stibnite-bearing material and, initially, produce antimony metal and military grade trisulfide as part of the U.S. DoW project, to commence following receipt of final permits.

A modular design provides Nova with the flexibility to scale operations over time, and respond to evolving market requirements including building an integrated domestic antimony supply chain within the United States.

Estelle Site Infrastructure Construction

• Korbel-Stibium Access Road: Construction of the Korbel-Stibium access road is progressing at pace, with the project set to provide year-round overland access to the northern prospects, including the Stibium antimony-gold prospect and the Korbel gold deposit, while delivering significant cost savings by reducing reliance on helicopter support (Figure 3).
• Whiskey Bravo Airstrip Expansion: Construction of the Whiskey Bravo airstrip expansion and apron continues, with the aim to upgrade specification to suit C-130 Hercules size aircraft (Figure 4). Along with significant freight cost savings, the expansion will allow increased freight size and payload capacity from the current 7,000lbs (DC-3) to 42,000lbs (C-130).
• RPM Road Alignment: The proposed RPM road alignment has been established with initial environmental baseline studies now completed in preparation for permitting application.
• Onsite Crushing and Ore Sorting Facility: Steel fabrication and site preparation is ongoing at the Whiskey Bravo crushing and ore sorting facility at the Estelle camp. The facility will play a key role in producing a coarse intermediate concentrate for transport to the Port MacKenzie downstream processing and refining plant, where antimony metal and military grade trisulfide will be produced under the $43.4 million DoW award.

2026 Estelle Field Season Completed

In parallel to establishing the Port MacKenzie refinery, Nova’s 2026 field season at Estelle has concluded. Nova completed ~8,000m of drilling, with three diamond core rigs operating around the clock, seven days a week, between June and September to leverage the longer daylight hours over the Alaskan summer.

• RPM: Several drill pads were established at RPM to focus on infill and expansion drilling, with approximately 4,200m completed at the deposit with the objective of further delineating the eastern strike extension at RPM North and increasing resource confidence at RPM Valley.

  Drilling at RPM also included approximately 1,500m of near-deposit expansion targets along the ridgeline north of RPM North where previous surface sampling and geophysics identified potential for additional high-grade, RPM-style gold mineralization.

  Outside of drilling, detailed geologic mapping was undertaken at RPM, as well as surface reconnaissance work between RPM and the Revelation prospect where previous surface sampling returned rock chip assays up to 24.6 grams per tonne gold.

  Drill samples have been logged, prepared, and shipped to the ALS laboratory for analysis.

• Korbel: Throughout the 2026 field season, PFS metallurgical test work, environmental and other technical studies continued at the Korbel deposit.

  Korbel will comprise a significant portion of the ore volume in any future mining scenario at Estelle.

• Stibium: At the Stibium antimony-gold prospect, Nova completed approximately 800m of targeted drilling across gold and stibnite (antimony) anomalies identified in surface sampling, with drilling occurring from a newly-established pad on the south face of the prospect, lower down on the slope and 200m closer to the target zone.
• Portage Pass: A detailed soils grid was conducted across the Portage Pass valley area with assays anticipated in the coming months.
• Stoney: One 415m drill hole was drilled at the end of the season targeting the Massive Au-Ag-Cu-Sb bearing Stoney Vein.
• West Wing: Detailed mapping and sampling were completed at West Wing, with samples sent to ALS and assays expected in the coming months.
• Train: Two holes were drilled at Train for approximately 475m, targeting a sheeted vein set with high-grade surface samples returning up to 128 g/t Au.
• Styx: During the field season, Nova drilled approximately 500m over two holes from the newly constructed drill pad on the eastern side of Styx to test the 1m-thick quartz-stibnite vein at the prospect.

In parallel, the Company extracted 100 tons of antimony ore to provide initial feed material for downstream processing and refining at the Port MacKenzie plant once construction has been completed.

Figure 1. Ball mill delivered to Alaska

Figure 2. Port MacKenzie antimony processing plant site early earthworks

Figure 3. Korbel-Stibium access road construction works

Figure 4. Whiskey Bravo airstrip expansion construction works

About Nova Minerals Corp

Nova Minerals Corp is advancing one of the world’s largest undeveloped gold deposits into production and securing a US domestic supply of the critical mineral antimony. The Company is focused on the exploration and development of the Estelle Gold and Critical Minerals Project, located in Alaska, a tier-one mining jurisdiction.

Estelle hosts two defined multi-million-ounce gold resources, and more than 20 prospects distributed along a 35-kilometre mineralized trend, in the prolific Tintina Gold Belt, a province which hosts a >220 million ounce (Moz) documented gold endowment and some of the world’s largest gold mines and discoveries including Kinross Gold Corporation’s Fort Knox Gold Mine. In parallel, Nova is advancing its critical minerals strategy, fully-funded by a $43.4 million U.S. Department of War award to develop a domestic antimony supply chain, targeted for production in 2027.

Further discussion and analysis of the Estelle Project is available through the interactive Vrify 3D animations, presentations, and videos, all available on the Company’s website www.novamineralscorp.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical fact, contained in this press release are forward-looking statements and that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Nova Minerals Corp’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Forward-looking statements contained in this announcement are made as of this date, and Nova Minerals Corp undertakes no duty to update such information except as required under applicable law.

For further information:

Nova Minerals:	Media:	Investor Relations:
Craig Bentley	Jenna Shinderman	Dave Gentry, CEO
Director	Sodali & Co	RedChip Companies, Inc.
Ph: 1-720-550-4223	Ph: 1-631-918-4047	Ph: 1-407-644-4256
E: craig@novamineralscorp.com	E: jenna.shinderman@sodali.com	E: NVA@redchip.com

SHENZHEN, China, Oct. 08, 2026 (GLOBE NEWSWIRE) — Huize Holding Limited (“Huize” or the “Company”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced that Ron Tam, Co-CFO of Huize and CEO of Poni Insurtech, Huize’s international arm, will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Huize Holding Limited is scheduled to present on Wednesday, October 21, 2026, at 2:00 p.m. PT. Ron will represent the Company.

Presentation Details

• Date: Wednesday, October 21, 2026
• Time: 2:00 p.m. PT (Track 3)
• Location: Luxe Sunset Boulevard Hotel, Los Angeles, California
• Webcast: https://ldmicroevents.com/

About Huize

Huize Holding Limited is a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia. Targeting mass affluent consumers, Huize is dedicated to serving consumers for their life-long insurance needs. Its online-to-offline integrated insurance ecosystem covers the entire insurance life cycle and offers consumers a wide spectrum of insurance products, one-stop services, and a streamlined transaction experience across all scenarios. By leveraging AI, data analytics, and digital capabilities, Huize empowers the insurance service chain with proprietary technology-enabled solutions for insurance consultation, user engagement, marketing, risk management, and claims service.

For more information, please visit http://ir.huize.com or follow us on social media via LinkedIn (https://www.linkedin.com/company/huize-holding-limited), X (https://x.com/huizeholding) and Webull (https://www.webull.com/quote/nasdaq-huiz).

About the LD Micro Main Event XX

The 20th Annual LD Micro Main Event will take place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles. Registration begins at 2:00 PM PT on Monday, October 19, followed by keynote programming and a networking reception.

Company presentations will run from 9:00 AM PT to 4:00 PM PT on Tuesday, October 20 and Wednesday, October 21. The event will feature more than 100 public companies presenting to and participating in private meetings with investors. Wednesday’s program will conclude with the LD Micro Moneyball Afterparty.

About LD Micro

LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Through its dynamic, investor-driven conferences and curated company exposure, LD has served as an invaluable asset to all those interested in discovering the next generation of great companies. For more information on LD Micro, visit www.ldmicro.com.

To present or register, please contact: registration@ldmicro.com

For investor and media inquiries, please contact:

Investor Relations
investor@huize.com

Media Relations
mediacenter@huize.com

Christensen Advisory
Dolly Zhang
Phone: +852 6996 4179
Email: dolly.zhang@christensencomms.com

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Eleco Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	07/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	1,151,000	1.36%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,151,000	1.36%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
1p Ordinary Shares	Sale	990	230.03p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
1p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	08/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

MONACO, Oct. 08, 2026 (GLOBE NEWSWIRE) — Costamare Bulkers Holdings Limited (the “Company”) (NYSE: CMDB), an international owner and operator of dry bulk vessels, announced the election of one Class I director at the Company’s virtual annual meeting of stockholders held today.

The elected Class I director is Dimitrios Sofianopoulos, who was elected to hold office for a term ending at the annual meeting of stockholders in 2029 and until his successor has been duly elected and qualified.

Stockholders also ratified the appointment of Ernst & Young (Hellas) Certified Auditors Accountants S.A. as the Company’s independent auditors for the fiscal year ending December 31, 2026.

About Costamare Bulkers Holdings Limited

Costamare Bulkers Holdings Limited is an international owner and operator of dry bulk vessels. Costamare Bulkers’ owned dry bulk fleet consists of 30 vessels (including one vessel we have agreed to sell) with a total carrying capacity of approximately 2,665,000 DWT. Costamare Bulkers also owns a dry bulk operating platform (CBI) which charters in/out dry bulk vessels, enters into contracts of affreightment, forward freight agreements and may also utilize hedging solutions. Costamare Bulkers’ common stock trades on the New York Stock Exchange under the symbol “CMDB”.

Forward-Looking Statements

This press release contains “forward-looking statements”. In some cases, you can identify these statements by forward-looking words such as “believe”, “intend”, “anticipate”, “estimate”, “project”, “forecast”, “plan”, “potential”, “may”, “should”, “could”, “expect” and similar expressions. You should not place undue reliance on these statements. These statements are not historical facts but instead represent only the Company’s beliefs regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Although the Company believes that its expectations stated in this press release are based on reasonable assumptions, it is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company’s Annual Report on Form 20-F (File No. 001-42581).
All forward-looking statements reflect management’s current views with respect to certain future events, and the Company expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in the Company’s views or expectations, or otherwise.

Company Contacts:
Gregory Zikos – Chief Executive Officer
Dimitris Pagratis – Chief Financial Officer
Konstantinos Tsakalidis – Business Development

Costamare Bulkers Holdings Limited, Monaco
Tel: (+377) 92 00 1745
Email: ir@costamarebulkers.com

Data-first workflow lets lenders review credit insights before purchasing scores

CHICAGO, Oct. 08, 2026 (GLOBE NEWSWIRE) — TransUnion (NYSE: TRU) today launched TransUnion First Look Functionality for Mortgage, enabling mortgage lenders to review credit insights before purchasing scores. The innovation follows TransUnion’s recent extension of 99-cent VantageScore® 4.0 mortgage pricing through 2028, with no charge when lenders pull it alongside a FICO® Score. Combined, these advancements help lenders improve origination efficiency, reduce costs and align credit spending more closely with loan progression.

Traditional mortgage workflows often require lenders to purchase credit scores early, even when the underlying credit data often provides the necessary information to determine whether a loan should advance, follow a streamlined path, or be removed from consideration. Whether using a soft-pull solution such as TruVision® Early Access Soft Check or a traditional hard-pull workflow, lenders frequently need multiple scores throughout the origination process. Purchasing those scores before they are needed can lead to unnecessary fallout costs for lenders.

“Mortgage lenders face sustained pressure to control costs and operate more efficiently without compromising underwriting decisions. TransUnion First Look Functionality for Mortgage allows lenders to start with credit report insights and add additional score-based decisioning only when needed,” said Satyan Merchant, senior vice president and mortgage business leader at TransUnion. “First Look Functionality provides insight earlier in the lending journey, directs resources toward the most promising opportunities and creates a more efficient path from application to closing.” 

With TransUnion First Look Functionality for Mortgage, lenders can evaluate early-stage risk by purchasing either a credit report alone or a credit report with the score of their choice, then request additional score(s) only when needed. Lenders do not incur the cost of a second credit report when adding additional score(s) when all eligibility and matching conditions are met. Additionally, TransUnion First Look Functionality for Mortgage is compatible with government-sponsored enterprises (GSEs) and the Federal Housing Administration (FHA) automated underwriting workflows, enabling seamless implementation without requiring changes to existing selling guidelines or policies.

Available for both soft- and hard-pull workflows and through mortgage resellers, lenders can capture efficiencies without redesigning existing processes. For instance, through Early Access Soft Check, lenders can assess borrower eligibility earlier by using the TransUnion credit report along with VantageScore 4.0, in addition to indicators on the credit report such as bankruptcy risk, streamlined-program eligibility and other underwriting considerations, before another score is needed.

Trended credit data and optional solutions like TruVision Alternative Credit Attributes and TruVision Income and Employment Verification can also provide additional insight in both soft and hard-pull workflows while helping reduce unnecessary credit expenses and maintain decision quality.
  
Learn more about TransUnion First Look Functionality for Mortgage. 

About TransUnion (NYSE: TRU)

TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments, we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

http://www.transunion.com/business

Contact	Dave Blumberg
	TransUnion
E-mail	david.blumberg@transunion.com
Telephone	312-972-6646

SEATTLE, Oct. 08, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of PSV359 for adult patients with locally advanced unresectable and/or metastatic fibroblast activation protein (FAP)-positive solitary fibrous tumors (SFTs).

SFT is a rare cancer for which patients with locally advanced unresectable or metastatic disease have limited treatment options. [²¹²Pb]PSV359 is an investigational FAP-targeted alpha-particle therapy being evaluated in an ongoing Phase 1/2a study in patients with advanced FAP-positive solid tumors. Published clinical imaging research has demonstrated FAP-targeted tracer uptake in SFTs, supporting the biological rationale for evaluating a FAP-directed therapy in this disease.¹ Early human imaging data for PSV359 support strong tumor uptake and fast renal clearance.

The FDA’s Fast Track program is intended to facilitate development and expedite the review of therapies for serious conditions with unmet medical needs.² Programs that receive Fast Track Designation may benefit from more frequent interactions with the FDA regarding the development program. A Fast Track-designated product may also qualify for rolling review, Accelerated Approval, or Priority Review if the applicable requirements for those programs are met.² FDA treats these as distinct expedited programs with separate qualifying criteria.

“FAP-α is a particularly compelling target because of its broad expression across solid tumors and within the tumor microenvironment, creating the potential for PSV359 to address a substantial patient population across multiple cancer types,” said Markus Puhlmann, Perspective’s Chief Medical Officer. “There are currently no approved therapies specifically targeting FAP-α, despite its association with aggressive cancers and tumor environments that can limit drug penetration and suppress immune activity. Imaging FAP-α expression before treatment allows us to pair patient selection with targeted alpha radiopharmaceutical therapy and pursue that broad opportunity with precision.”

“Fast Track designation for FAP-positive solitary fibrous tumors is an important step in advancing the broader PSV359 program and our strategy of engineering targeted radiopharmaceutical therapy based on the alpha-generating isotope ²¹²Pb to optimize the therapeutic window in oncology,” said Thijs Spoor, Perspective’s Chief Executive Officer. “We look forward to working with the FDA and the medical community to define an efficient development path for PSV359 in this rare and serious disease.”

About FAP

FAP is a cell-surface protein expressed predominantly by cancer-associated fibroblasts (CAFs) in the stroma, an important component of the tumor microenvironment (TME) in many epithelial cancers. FAP may also be expressed directly by certain cancer cells, including sarcomas and mesotheliomas.^3,4,5,6 Higher FAP-α expression has been found to be associated with poor prognosis in a number of solid tumors such as non-small cell lung cancer, colorectal cancer, pancreatic cancer, stomach cancer, mesothelioma, head and neck cancer, esophageal cancer, and ovarian cancer.^{7,8,9,10,11,12} FAP-α expression is generally limited in healthy tissues.^5,6

About PSV359

PSV359 was designed to target and deliver ²¹²Pb to tumor sites expressing FAP-α, associated with multiple highly prevalent solid tumors, with patients in need of additional treatment options. The targeting moiety may also be radiolabeled with ²⁰³Pb or ⁶⁸Ga (known as PSV377) to detect FAP-α expression in individual patients. Preclinical imaging and therapy, as well as early human imaging results, have demonstrated that Perspective’s proprietary targeting ligand improves target engagement and uptake in tumors and reduces retention in healthy tissues, which may result in a desirable therapeutic index.

Perspective is conducting a multi-center, open-label, dose-finding and dose-expansion study (clinicaltrials.gov identifier NCT06710756) of [²¹²Pb]PSV359 in patients with advanced solid tumors that express FAP-α as determined by imaging with [²⁰³Pb]PSV359. The primary objective of the dose-finding phase of the study is to assess the safety and tolerability of various doses of [²¹²Pb]PSV359 in order to inform selection of the recommended Phase 2 dose for use in the expansion phase. Antitumor activity may be evaluated as an additional primary outcome in the expansion portion of the study.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s proprietary technology, imaging techniques and product candidates, including PSV359, and related treatment opportunities; the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs, including the potential for PSV359 to address a substantial patient populations across multiple cancer types; the anticipated clinical benefits of the Company’s product candidates relative to existing therapies; the Company’s expectations regarding regulatory pathways for its product candidates; the expected benefits regarding the U.S. Food and Drug Administration’s (“FDA”) Fast Track Designation for PSV359, and PSV359’s potential eligibility for accelerated approval, priority review and rolling review; the Company’s expectations regarding its interactions with regulatory agencies, including the FDA, and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include (without limitation) that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; regulatory authorities may not grant or may delay approval for our product candidates; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; FDA’s designation for PSV359 may not provide the anticipated benefits and could be subject to withdrawal; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

---

¹ Hamacher R, Pabst KM, Cheung PF, et al. Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor. J Nucl Med. 2024;65(2):252-257. Published 2024 Feb 1. doi:10.2967/jnumed.123.266411
² Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics. https://www.fda.gov/media/86377/download?attachment. Accessed September 9, 2026.
³ Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87(18):7235-7239. doi:10.1073/pnas.87.18.7235
⁴ Dziadek S, Kraxner A, Cheng WY, et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Front Immunol. 2024;15:1352615. Published 2024 Mar 15. doi:10.3389/fimmu.2024.1352615
⁵ Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-805. doi:10.2967/jnumed.119.227967
⁶ Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803. doi:10.1007/s10555-020-09909-3
⁷ Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42(3):396-412.e5. doi:10.1016/j.ccell.2023.12.021
⁸ Coto-Llerena M, Ercan C, Kancherla V, et al. High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes. Front Oncol. 2020;10:979. Published 2020 Jul 8. doi:10.3389/fonc.2020.00979
⁹ Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res. 2007;13(6):1736-1741. doi:10.1158/1078-0432.CCR-06-1746
¹⁰ Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6(1):249. Published 2021 Jul 5. doi:10.1038/s41392-021-00659-4
¹¹ Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154-158. doi:10.1097/MPA.0b013e31816618ce
¹² Ma C, Xi S, Sun, H, et al. Identifying the oncogenic roles of FAP in human cancers based on systematic analysis. Aging 2023;15(14):7056-7083. doi: 10.18632/aging.204892

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Man Group PLC
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Rotork Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	07/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.5p ordinary
	Interests		Short positions
	Number	%		Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	15,542,057	1.90		11,211	0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	15,542,057	1.90		11,211	0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.5p ordinary	Equity swap	Increasing a long position	81	4.8860 GBP
0.5p ordinary	Equity swap	Increasing a long position	1,299	4.8860 GBP
0.5p ordinary	Equity swap	Increasing a long position	23	4.8860 GBP

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	08/10/2026
Contact name:	Graham Keene
Telephone number:	+44 20 7144 2259

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

METTAWA, Ill., Oct. 08, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2026 third quarter financial results on Thursday, October 29, 2026, before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website. The results will also be available on the SEC’s website with the Form 8-K filing of the release.

The Company will hold a conference call at 10 a.m. CT / 11 a.m. ET, Thursday, October 29, 2026, hosted by David M. Foulkes, chairman and chief executive officer, Ryan M. Gwillim, executive vice president, chief financial officer, and chief strategy officer, Aine Denari, executive vice president, president Navico Group, and Brunswick chief technology officer, and Stephen Weiland, senior vice president, finance, and deputy CFO. A copy of the presentation to be used on this call will be available when the results are released as noted above.

The webcast can be accessed at Brunswick.com and here:  Webcast | Brunswick Corporation Q3 2026 Earnings Conference Call. A replay of the conference call will be available through 1 p.m. CT Thursday November 5, 2026, at the same link.

About Brunswick Corporation

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion (including Mercury Marine), parts and accessories (including Attwood), and marine electronics (including Simrad and Lowrance), as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund, and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,000 employees operating in 26 countries. Learn more at Brunswick.com.

Forward-Looking Statements

Certain statements in this news release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations, estimates, and projections about Brunswick’s business and by their nature address matters that are, to different degrees, uncertain. Words such as “may,” “could,” “should,” “will,” “expect,” “anticipate,” “project,” “position,” “intend,” “target,” “plan,” “seek,” “estimate,” “believe,” “predict,” “outlook,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties that may cause actual results to differ materially from expectations as of the date of this news release. These risks include, but are not limited to: the effect of adverse general economic conditions, including rising interest rates, and the amount of disposable income consumers have available for discretionary spending; changes to trade policy and tariffs, including retaliatory tariffs; fiscal and monetary policy changes; adverse capital market conditions; changes in currency exchange rates; competitive pricing pressures; higher energy and fuel costs; managing our manufacturing footprint and operations; loss of key customers; international business risks, geopolitical tensions or conflicts, sanctions, embargoes, or other regulations; actual or anticipated increases in costs, disruptions of supply, or defects in raw materials, parts, or components we purchase from third parties; supplier manufacturing constraints, increased demand for shipping carriers, and transportation disruptions; adverse weather conditions, climate change events and other catastrophic event risks; our ability to develop new and innovative products and services at a competitive price; absorbing fixed costs in production; our ability to meet demand in a rapidly changing environment; public health emergencies or pandemics; our ability to successfully implement our strategic plan and growth initiatives; attracting and retaining skilled labor, implementing succession plans for key leadership and executing organizational and leadership changes; our ability to integrate acquisitions and the risk for associated disruption to our business; the risk that restructuring or strategic divestitures will not provide business benefits; our ability to identify and complete targeted acquisitions; maintaining effective distribution; dealer and customer ability to access adequate financing; inventory reductions by dealers, retailers, or independent boat builders; requirements for us to repurchase inventory; risks related to the Freedom Boat Club franchise business model; outages, breaches, or other cybersecurity events regarding our technology systems, which have affected and could further affect manufacturing and business operations and could result in lost or stolen information and associated remediation costs; our ability to protect our brands and intellectual property; an impairment to the value of goodwill and other assets; product liability, warranty, and other claims risks; legal, environmental, and other regulatory compliance, including increased costs, fines, and reputational risks; risks associated with joint ventures that do not operate solely for our benefit; changes in income tax legislation or enforcement; managing our share repurchases; and risks associated with certain divisive shareholder activist actions.

Additional risk factors are included in the Company’s Annual Report on Form 10-K for 2025 and in subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date on which they are made, and Brunswick does not undertake any obligation to update them to reflect events or circumstances after the date of this news release.

CONTACT: Lee
Gordon —
Chief Communications Officer
M: (904) 860-8848 | O: (847) 735-4003

MONTREAL, Oct. 08, 2026 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; “BRW” or the “Company”) is pleased to announce the assays of the previously announced 202-metre interval (see press release dated September 17 2026) at its Anatacau Main Project, located 20 km east of Rio Tinto’s Galaxy project, in the Eeyou Istchee James Bay region of Quebec.

This intercept is a significant discovery for Brunswick Exploration and will be the focus of future exploration work.

Highlights include:

• Results confirmed the mineralization of the Anais dyke observed in drill hole AN-25-15 with an intercept of 202.45 meters returning 1.31% Li2O from 274.25 to 476.70 meters.
• Higher grade core of 85 meters grading 1.73% Li2O represents a substantial jump in grade observed to date at Anais.
• The Anais dyke remains open in all directions and has significantly expanded following this drill hole.
• Drill hole AN-26-15 also returned two other major pegmatitic intervals: 1.41% Li2O over 21.5 meters and 1.28% Li2O over 9.2 meters. Both intercepts are separate from the Anais dyke and point to a much wider mineralized system at Anatacau.
• More results are pending.

Mr. Killian Charles, President and CEO of BRW, commented: “Anais is rapidly improving, not just in width, as the considerable length of the intercept highlights, but also in grade. These assay results are extremely encouraging and underscore the potential that exists at Anais. Importantly, we remain at the start of the discovery process. Anais is open in all directions. Over the course of the last twelve months, every drill hole that intercepted the main dyke has consistently grown it. We believe this trend will continue. Excitingly, drilling is still ongoing at Anatacau and I am looking forward to discussing future results with existing and prospective shareholders.”

Figure 1: Surface Map of the Anatacau Main Project and Drill Holes Completed

Figure 2: Cross Section A-A’ (see Figure 1 for Location)

Figure 3: Regional Map of the Anatacau Main and Anatacau West Projects

Discussion of Results

To date, a total of four holes totaling approximately 1,700 meters have been drilled in the Anais sector, with all assay results pending except for hole AN-26-15.

Hole AN-26-15 returned three major pegmatitic intervals: 1.28% Li2O over 9.2 meters, 1.41% Li2O over 21.50 meters, and 1.31% Li2O over 202.45 meters, confirming the Anais Main dyke to a vertical depth of 300 meters. The 202.45 meters intercept contained an 85.75 meter high-grade zone returning 1.73% Li2O. These pegmatite intervals contain between 10-30% spodumene crystals, and are generally coarse grained, pale colored and unaltered. Mica, predominantly muscovite, and other accessory mineral content is low. The combination of large spodumene crystals and low accessory mineral content should be well represented in future planned metallurgical studies. Preliminary review of the upper and lower contact of the intercept suggests that the Anais dyke changes from a sub vertical dip near surface to a shallower 45 degrees dip a depth. Further drilling will seek to confirm this change in orientation.

Table 1: Results from AN-26-25

Hole ID	From (m)	To (m)	Core length (m)	Li2O (%)
AN-26-15	170.8	180	9.2	1.28
	211.4	232.9	21.5	1.41
	274.25	476.7	202.45	1.31
	including
	298.4	384.15	85.75	1.73

*The true thickness of the Anais dyke is estimated to be approximately 75%
**Interval total can contain up to 25% country rocks

Table 2: Drill Hole Collars (UTM Nad83, Zone 18N)

Drill Holes	Azimuth	Dip	Length (m)	UTM X	UTM Y	Elevation (m)
AN-26-15	125	52	498	380198	5784693	198

Note

SEC Technical Report Summary for the James Bay Lithium Project prepared by SLR Consulting (Canada), Wave International Pty and WSP Canada for Arcadium Lithium Plc., dated August 31, 2023.

QAQC

All drill core samples were collected under the supervision of BRW employees and services contractor Explo-Logik, applying industry-standard QA/QC procedures to its drilling and prospecting programs. All sample preparation and analytical work were performed by Agat Laboratories. Samples were be prepared with methods 200075 and 200087 and dissolved in a sodium peroxide solution, prior to multielement analysis by ICP-OES and ICP-MS according to the Agat method 201378. All results passed the QA/QC screening at the laboratory, and all inserted standard, duplicates and blanks returned results within acceptable limits.

Qualified Person

The scientific and technical information contained in this press release has been reviewed and approved by Mr. Simon T. Hébert, VP Development. He is a Professional Geologist registered in Quebec and is a Qualified Person as defined by National Instrument 43-101.

About Brunswick Exploration

Brunswick Exploration is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. The Company is focused on grassroots exploration for lithium in Canada, a critical metal necessary to global decarbonization and energy transition. The company is rapidly advancing the most extensive grassroots lithium property portfolio in Canada, Greenland and Saudi Arabia underpinned by its Mirage project, one of the largest undeveloped hard-rock lithium Inferred Mineral Resource Estimate in the Americas, with 52.2Mt grading 1.08% Li2O.

Investor Relations/information

Mr. Killian Charles, President and CEO (info@BRWexplo.com)

Contact number: 514 861 4441

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c005fd65-6c6f-465b-bc30-71513584a3c6
https://www.globenewswire.com/NewsRoom/AttachmentNg/af2fce1d-9bca-48e7-bc95-c5a260ea4f4d
https://www.globenewswire.com/NewsRoom/AttachmentNg/4645b5ba-c73d-4b86-8acb-9d6d536f1702